Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


17.09.2018

1 Am J Clin Oncol
3 Anticancer Res
2 BJU Int
1 BMC Urol
1 Br J Radiol
1 Cancer Lett
3 Clin Cancer Res
1 Eur Radiol
1 Eur Urol
2 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
2 J Natl Cancer Inst
1 J Nucl Med
1 J Urol
2 Lancet Oncol
1 N Engl J Med
1 Oncogene
1 Oncology (Williston Park)
2 PLoS One
1 Prog Urol
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. WALE DJ, Viglianti BL, Gross MD, Ferretti A, et al
    Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
    Am J Clin Oncol. 2018 Sep 10. doi: 10.1097/COC.0000000000000479.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. PONTI G, Maccaferri M, Micali S, Manfredini M, et al
    Seminal Cell Free DNA Concentration Levels Discriminate Between Prostate Cancer and Benign Prostatic Hyperplasia.
    Anticancer Res. 2018;38:5121-5125.
    PubMed     Text format     Abstract available

  3. HUNG SC, Wang SS, Li JR, Chen MC, et al
    Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate.
    Anticancer Res. 2018;38:5429-5436.
    PubMed     Text format     Abstract available

  4. NAM RK, Wallis CJD, Amemiya Y, Benatar T, et al
    Identification of a Novel MicroRNA Panel Associated with Metastasis Following Radical Prostatectomy for Prostate Cancer.
    Anticancer Res. 2018;38:5027-5034.
    PubMed     Text format     Abstract available


    BJU Int

  5. VAN ROMPAY MI, Nickel JC, Ranganathan G, Kantoff PW, et al
    Impact of 5alpha-Reductase Inhibitors and alpha-Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality.
    BJU Int. 2018 Sep 14. doi: 10.1111/bju.14534.
    PubMed     Text format     Abstract available

  6. STEUBER T, Tennstedt P, Macagno A, Athanasiou A, et al
    Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies.
    BJU Int. 2018 Sep 14. doi: 10.1111/bju.14540.
    PubMed     Text format     Abstract available


    BMC Urol

  7. OUELLET V, Aprikian A, Bergeron A, Brimo F, et al
    The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
    BMC Urol. 2018;18:78.
    PubMed     Text format     Abstract available


    Br J Radiol

  8. HEDGIRE S, Kilcoyne A, Tonyushkin A, Mao Y, et al
    Effect of androgen deprivation and radiation therapy on MRI fiber tractography in prostate cancer: Can we assess treatment response on imaging?
    Br J Radiol. 2018 Sep 13:20170170. doi: 10.1259/bjr.20170170.
    PubMed     Text format     Abstract available


    Cancer Lett

  9. DELLIAUX C, Tian TV, Bouchet M, Fradet A, et al
    TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
    Cancer Lett. 2018 Sep 7. pii: S0304-3835(18)30551.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  10. DE LAERE B, Oeyen S, Mayrhofer M, Whitington T, et al
    TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2018 Sep 12. pii: 1078-0432.CCR-18-1943.
    PubMed     Text format     Abstract available

  11. ZHANG T, George DJ, Armstrong AJ
    Precision medicine approaches when prostate cancer Akts up.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-2491.
    PubMed     Text format     Abstract available

  12. KULARATNE SA, Thomas M, Myers CH, Gagare P, et al
    Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery for Prostate Cancer.
    Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-0803.
    PubMed     Text format     Abstract available


    Eur Radiol

  13. FISCHBACH F, Wien L, Krueger S, Schnackenburg B, et al
    Feasibility study of MR-guided transgluteal targeted in-bore biopsy for suspicious lesions of the prostate at 3 Tesla using a freehand approach.
    Eur Radiol. 2018;28:2690-2699.
    PubMed     Text format     Abstract available


    Eur Urol

  14. WALLIS CJD, Krakowsky Y, Finelli A
    Low Testosterone and Prostate Cancer: Is the Protection Real?
    Eur Urol. 2018 Sep 5. pii: S0302-2838(18)30616.
    PubMed     Text format    


    Int J Radiat Oncol Biol Phys

  15. EVANS JD, Morris LK, Zhang H, Cao S, et al
    Prospective Immunophenotyping of CD8(+) T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed SBRT.
    Int J Radiat Oncol Biol Phys. 2018 Sep 8. pii: S0360-3016(18)33725.
    PubMed     Text format     Abstract available

  16. SOLDATOV A, von Klot CAJ, Walacides D, Derlin T, et al
    Patterns of progression after (68)Ga-PSMA-ligand PET/CT-guided radiotherapy for recurrent prostate cancer.
    Int J Radiat Oncol Biol Phys. 2018 Sep 7. pii: S0360-3016(18)33708.
    PubMed     Text format     Abstract available


    J Clin Oncol

  17. GOMEZ-ITURRIAGA A, Crook J
    High-Risk Localized Prostate Cancer: How Important Is the Addition of Brachytherapy to External-Beam Radiotherapy?
    J Clin Oncol. 2018 Sep 13:JCO1800704. doi: 10.1200/JCO.18.00704.
    PubMed     Text format    


    J Natl Cancer Inst

  18. MEIER KE
    Omega-3 Fatty Acids and Prostate Cancer: G Protein-Coupled Receptors to the Rescue.
    J Natl Cancer Inst. 2018 Sep 6. pii: 5091908. doi: 10.1093.
    PubMed     Text format    

  19. LIANG P, Henning SM, Guan J, Grogan T, et al
    Role of Host GPR120 in Mediating Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer.
    J Natl Cancer Inst. 2018 Sep 6. pii: 5091911. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Nucl Med

  20. JADVAR H
    Radiotheranostics in Prostate Cancer: Introduction and Overview.
    J Nucl Med. 2016;57.
    PubMed     Text format    


    J Urol

  21. KAPLAN SA
    Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease.
    J Urol. 2016;196:1713-1714.
    PubMed     Text format    


    Lancet Oncol

  22. SEYMOUR Z, Hamstra D
    Quality of life is not compromised with intensification of androgen therapy in recurrent prostate cancer.
    Lancet Oncol. 2018 Sep 10. pii: S1470-2045(18)30567.
    PubMed     Text format    

  23. SAAD F, Cella D, Basch E, Hadaschik BA, et al
    Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2018 Sep 10. pii: S1470-2045(18)30456.
    PubMed     Text format     Abstract available


    N Engl J Med

  24. ANTONARAKIS ES
    Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.
    N Engl J Med. 2018;379:1087-1089.
    PubMed     Text format    


    Oncogene

  25. STYLIANOU N, Lehman ML, Wang C, Fard AT, et al
    A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.
    Oncogene. 2018 Sep 7. pii: 10.1038/s41388-018-0488.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  26. ROBIN TP, Maroni PD, Chin BB, La Rosa FG, et al
    Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification.
    Oncology (Williston Park). 2018;32:360-3.
    PubMed     Text format    


    PLoS One

  27. HASAN D, Gamen E, Abu Tarboush N, Ismail Y, et al
    PKM2 and HIF-1alpha regulation in prostate cancer cell lines.
    PLoS One. 2018;13:e0203745.
    PubMed     Text format     Abstract available

  28. MOSES-FYNN E, Tang W, Beyene D, Apprey V, et al
    Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men.
    PLoS One. 2018;13:e0203322.
    PubMed     Text format     Abstract available


    Prog Urol

  29. AOUN F, Slaoui A, Walid EHO, Albisinni S, et al
    Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
    Prog Urol. 2018 Sep 7. pii: S1166-7087(18)30182.
    PubMed     Text format     Abstract available


    Urology

  30. OBMANN VC, Pahwa S, Tabayayong W, Jiang Y, et al
    Diagnostic accuracy of a rapid biparametric MRI protocol for detection of histologically proven prostate cancer.
    Urology. 2018 Sep 7. pii: S0090-4295(18)30920.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: